Cited by 13,818Nutrition and Health in AgingFrailty in Older AdultsMuscle Physiology and Disorders

Sarcopenia: revised European consensus on definition and diagnosis

Open access
Cruz-Jentoft, Alfonso J, Bahat, Gülistan, Bauer, Jürgen, Boirie, Yves, Bruyère, Olivier, Cederholm, Tommy, Cooper, Cyrus, Landi, Francesco +22 more·2019·Age and Ageing

Abstract

Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ageing/afy169

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GS, TUG, SPPB, and 5STS are critical indicators of mobility, independence, and fall risk in older adults.

    “These variables are critical indicators of mobility, independence, and fall risk in older adults [3].”

    From Efficacy of Power Training on Sarcopenic Obesity in Community-Dwelling Older Women: A 32-Week Randomized Clinical Trial (2025) · cites this paper as [3]

    In “Measuring sarcopenia parameters” (page unavailable), the paper describes gait speed, SPPB and TUG as physical-performance or function tests, and the five-rise chair stand test as a measure of leg strength. It specifically links gait speed to disability and falls, but does not establish all four tests as indicators of independence and fall risk. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Individuals with obesity and low muscle mass, especially women and those with type 2 diabetes, prediabetes, or metabolic dysfunction-associated steatotic liver disease, are at high risk of sarcopenia, sarcopenic obesity, and serious negative health outcomes.

    “These individuals—and especially women and those with T2D, prediabetes, or metabolic dysfunction‐associated steatotic liver disease (MASLD)—are already at high risk of sarcopenia (age‐related loss of skeletal muscle function and mass), 30 , 31 sarcopenic obesity (the co‐existence of excess adiposity and low muscle mass/function, which can occur at any age 32 ), and the serious negative health out”

    From Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity (2025) · cites this paper as [28]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Sarcopenia definitions have evolved through European and Asian consensus updates that place greater emphasis on muscle strength and physical performance, while the ESPEN and EASO consensus and the Sarcopenic Obesity Global Leadership Initiative have attempted to standardize SO diagnosis and research priorities.

    “Sarcopenia definitions have evolved through European and Asian consensus updates that place greater emphasis on muscle strength and physical performance, while the ESPEN and EASO consensus and the Sarcopenic Obesity Global Leadership Initiative have attempted to standardize SO diagnosis and research priorities (2, 7–9).”

    From Exercise-based interventions for sarcopenic obesity in middle-aged and older adults: an umbrella review of systematic reviews with pairwise meta-analyses and network meta-analyses (2026) · cites this paper as [7]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • A major reason for variation in sarcopenic obesity prevalence is the method of adjusting muscle quantity for body size.

    “Indeed, a major reason for the variation in sarcopenic obesity prevalence is the method of adjusting muscle quantity for body size.46,47,55,57”

    From Changes in lean body mass with <scp>glucagon‐like peptide</scp> ‐1‐based therapies and mitigation strategies (2024) · cites this paper as [46]

    The Measuring sarcopenia parameters section (page not supplied) describes several ways to adjust muscle quantity for body size. The Sarcopenic obesity section (page not supplied) discusses prevalence but does not say that adjustment method is a major reason prevalence estimates vary. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • All regional working groups on the definition of sarcopenia have moved from recommending using lean mass alone to adding muscle strength and function, and switching focus from lean mass to muscle strength and function.

    “All regional working groups on the definition of sarcopenia have moved from recommending using lean mass alone to adding muscle strength and function, and switching the focus of the definition from lean mass to muscle strength and function.[46][47][48]”

    From Changes in lean body mass with <scp>glucagon‐like peptide</scp> ‐1‐based therapies and mitigation strategies (2024) · cites this paper as [46]

    The Sarcopenia: operational definition section says the earlier European definition added muscle function to definitions based only on low muscle mass, and that EWGSOP2 now places muscle strength at the forefront. But it uses physical performance to classify severity, not as a coequal focus of the core definition. This European consensus also does not establish what all regional working groups recommend. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 156 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Keller, 2018, Sarcopenia, Wien Med Wochenschr

Cited by

Sorted by citations

Authors
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., Zamboni, M., Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), A. T. E. G. F. E., Bautmans, I., Baeyens, J.-P., Cesari, M., Cherubini, A., Kanis, J., Maggio, M., Martin, F., Michel, J.-P., Pitkala, K., Reginster, J.-Y., Rizzoli, R., Sánchez-Rodríguez, D., & Schols, J.
Affiliations
  • Instituto Ramón y Cajal de Investigación Sanitaria (ES)
  • Istanbul University (TR)
  • Heidelberg University (DE)
  • Research Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
  • University of Liège (BE)
  • Uppsala University (SE)
  • University of Oxford (GB)
  • Università Cattolica del Sacro Cuore (IT)
  • Université de Toulouse (FR)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Université Côte d'Azur (FR)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Department of Geriatrics, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic
  • University of Antwerp (BE)
  • Amsterdam Public Health (NL)
  • University of Verona (IT)
  • University of Geneva (CH)
  • Vrije Universiteit Brussel (BE)
  • University of Luxembourg (LU)
  • University of Milan (IT)
  • Istituto Nazionale di Riposo e Cura per Anziani (IT)
  • University of Parma (IT)
  • Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Central Hospital, Unit of Primary Health Care; Helsinki, Finland
  • Geriatrics Department, Parc Salut Mar. Rehabilitation Research Group, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM). Universitat Autònoma de Barcelona, Universitat Pompeu Fabra; Barcelona, Spain
  • Maastricht University (NL)
Corresponding author
Cruz-Jentoft, Alfonso J
Venue
Age and Ageing
Published
2018-09-24
Volume
48
Issue
1
Pages
16-31
ISSN
  • 0002-0729 (ISSN-L)
  • 1468-2834
OpenAlex
W2897513125
Cited by
13,818
References
156
Citations by year
2026: 1514 · 2025: 2382 · 2024: 2262 · 2023: 2122 · 2022: 1909 · 2021: 1759 · 2020: 1234 · 2019: 580 · 2018: 25 · 2017: 2 · 2014: 2 · 2013: 3 · 2012: 6
FWCI
616.75
Type
journal article
Language
en
Open access
Locations
  • Age and Ageing (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • VU Research Portal (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, cc-by-nc)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • Lirias (submittedVersion)
  • ORBi (University of Liège) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc)
Funders
European Working Group on Sarcopenia in Older People 2
Topics
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
sarcopenia, sarcopenia definitions, sarcopenia diagnosis, muscle weakness, muscle mass, muscle quality, physical performance, sarcopenia severity, case-finding algorithms, cut-off values, older adults, EWGSOP2 criteria
MeSH terms
Europe, Humans, Biomarkers, Muscle, Skeletal, Biomedical Research, Muscle Strength, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review